Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Investor Presentation (February 2022)
24 slides from Little Green Pharma's investor presentation, Feb 2, 2022
Slide 1: Company Update
For personal use only ASX:LGP Company Update 2 February 2022 Our vision is to reimagine cannabis medicines and do extraordinary things for our patients Our purpose is to solve real patient problems
Slide 2: Disclaimer
Disclaimer For personal use only Disclaimer Not financial product advice This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 This document does not constitute financial product advice or take into account your 215) (“LGP”) and its activities current as at the da
Slide 3: Corporate Overview
Corporate Overview For personal use only Capital Structure Register Breakdown1 Current Share Price1 $0.545 Institutional Shares Outstanding1,2 236,211,216 36% Options and Performance Rights on Issue 16,940,536 Others Market Capitalisation (undiluted)1 ~$128.7 million 52% Cash Reserves (31 Dec 2021)
Slide 4: Investment Highlights
Investment Highlights LGP is uniquely positioned to supply pharmaceutical-grade cannabis medicines across the globe For personal use only Record half yearly sales revenue of ~$6.9m (unaudited) (+84% pcp) and record cash receipts of $6.5m Market leader in Record half yearly number of new prescribers
Slide 5: Business Model
For personal use only Business Model
Slide 6: Our Business Model Captures Value
Our Business Model Captures Value LGP operates across the entire medicinal cannabis supply chain For personal use only Cultivation & Manufacturing Product Patient Access Sales & Production Innovation & Education Distribution EU GACP greenhouse EU-recognised GMP R&D pipeline includes three QUEST Init
Slide 7: Growth Strategy
Growth Strategy Little Green Pharma has a track record of sales growth with a clear pathway to increasing For personal use only margins and driving significant revenue growth in Australia and offshore markets 1 Patient acquisition 2 3 Product and drug Clear pathway to in Australia international deli
Slide 8: Market Leader in Australia
Market Leader in Australia For personal use only
Slide 9: Solid Sales Track Record
Solid Sales Track Record Strong growth in sales and patients using LGP products For personal use only REVENUE FY 20 $2.2m FY 21 $7.0m H1 FY 22 $6.9m CASH AT BANK INTERNATIONAL UNITS NEW AUSTRALIAN SUPPLIED1 PATIENTS $40.2m 28,000 10,600 est $25.2m (13,000 for 16,000 French trial) ~8,500 316 (10,500
Slide 10: QUality-of-life, Evaluation Study – sponsored by LGP
For personal use only QUality-of-life, Evaluation Study – sponsored by LGP An Australian project, the QUEST Initiative, is the world’s largest longitudinal study investigating the quality of life and health economics on patients with chronic disease who have been prescribed medicinal cannabis Total
Slide 11: World Class Cultivation & Manufacturing Capability
World Class Cultivation & Manufacturing For personal use only Capability
Slide 12: LGP Australia
LGP Australia For personal use only TGA-GMP manufacturing facility licensed to produce flower, extracts (oils), tinctures and APIs1 Indoor GACP cultivation facility capacity ~3 tonnes p.a. biomass Option to double cultivation capacity with further expansion if necessary 1. LGP also has a separate ex
Slide 13: LGP Denmark
LGP Denmark For personal use only World class cannabis cultivation and manufacturing facility GACP cultivation and EU- recognised GMP manufacturing Exports to Australia, Germany and Czech Republic Production capacity of >20 tonnes p.a. biomass • 21,500m2 glasshouse house cultivation area • 4,000
Slide 14: LGP Denmark
LGP Denmark Recent GMP certification of internal analytical laboratory facility For personal use only Analytical laboratory competitive advantage: • Provide analytical services to third parties creating additional revenue stream • Inhouse capability ensures timely and cost-efficient testing abilitie
Slide 15: Dominant EU Distribution Platform – Strategic Positioning
Dominant EU Distribution Platform– For personal use only Strategic Positioning
Slide 16: Strategically Positioned in Europe
Strategically Positioned in Europe LGP has supply pathways For personal use only across Europe to access over 350m - 68% of the EU & UK population DANISH FACILITY Currently Selling In Strategically Positioned ~$1b MRA with Denmark ~$6b EU/UK Population: 515m ~$3b ~$8b LGP Total Addressable 350m Popu
Slide 17: Clear Pathway to International Sales
Clear Pathway to International Sales LGP’s Total Addressable Market (TAM) is 375m people and $38b For personal use only Population TAM Competitive Landscape Australia LGP, 35+ Australia’s first producer and exporter of medicinal cannabis with premium brand since August 2018 25m A$1b1 other 3 ton
Slide 18: Strong Product Innovation and R&D Pipeline
Strong Product Innovation and R&D Pipeline For personal use only
Slide 19: Product Innovation
Product Innovation Solving real patient problems For personal use only Meet the Market – LGP currently manufactures four LGP-branded cannabis flower medicines – product line two THC dominant strains, one CBD dominant strain and one balanced strain expansion 15 additional plant genetics have been
Slide 20: R&D Pipeline
R&D Pipeline INNOVATE DEVELOP LAUNCH REGISTRATION For personal use only • Identify key unmet patient • Patient focused drug design • Rapid path to market access • Market Authorisation needs • Launch new medicine in Australia (TGA, EMA, FDA) • Optimisation (SAS B) & global markets • Sponsor the QUEST
Slide 21: LGP Positioning
LGP Positioning LGP is uniquely positioned to supply pharmaceutical-grade For personal use only cannabis medicines across the globe Biomass capacity LGP’s cultivation capacity is >25 tonnes p.a. of cannabis biomass ensuring self sufficiency and long-term security of supply This capacity positions th
Slide 22: Our ESG commitment
Our ESG commitment LGP solves societal and environmental challenges through core business activities For personal use only SIX DIMENSIONS OF IMPACT Economic vitality H Access and inclusion M Environmental sustainability L 0 Societal enablement Lifetime well-being Ethical capacity 2 2 Source: Model b
Slide 23: News Flow – Making Solid Progress
News Flow – Making Solid Progress Significant commercial progress as LGP executes growth strategy For personal use only New distribution agreements in Europe (Denmark and Poland) Expansion of production output capabilities First offtake agreement from Danish facility First registered product in Denm
Slide 24: Connect
Connect Danish-made EU-GMP cannabis medicines For personal use only PO Box 690, West Perth Western AUSTRALIA 6872 P: +61 8 6280 0050 E: info@littlegreenpharma.com.au W: littlegreenpharma.com facebook.com/littlegreenpharma linkedin.com/company/little-green-pharma Australian-made TGA-GMP cannabis medi
Little Green Pharma — Investor Presentation (February 2022) on 6ix